The graft-versus-leukemia effect is able to induce clinical responses in patients with chronic lymphocytic leukemia treated with a reduced intensity conditioning regimen, followed by allogeneic stem cell transplantation. We investigated whether molecular remissions could be attained after reduced intensity conditioning and allogeneic stem cell transplantation in patients with relapsed chronic lymphocytic leukemia and whether the assessment of minimal residual disease might be used to predict the clinical outcome. DESIGN AND METHODS: Minimal residual disease was monitored by polymerase chain reaction using the immunoglobulin heavy-chain gene rearrangement as a molecular marker in 29 relapsed patients who achieved complete remission following...
Imatinib induces a high complete cytogenetic response (CCR) rate in relapsed chronic myelogenous leu...
Allogeneic stem cell transplantation (SCT) is the choice of therapy for leukemia patients who respon...
Current induction therapies for acute and chronic leukemias and the lymphomas have achieved signific...
BackgroundThe graft-versus-leukemia effect is able to induce clinical responses in patients with chr...
Background: The graft-versus-leukemia effect is able to induce clinical responses in patients with c...
The online version of this article contains a supplementary appendix. Background The graft-versus-le...
Reduced intensity allogeneic stem cell transplantation (RIC alloSCT) can lead to 50% of progression...
Background and Objectives: The molecular analysis of minimal residual disease (MRD) may provide info...
Quantification of minimal residual disease (MRD) following allogeneic hematopoietic cell transplanta...
In chronic lymphocytic leukemia (CLL), clonal rearrangement of the immunoglobulin heavy chain locus ...
Monitoring minimal residual disease is an important way to identify patients with acute myeloid leuk...
Patients in complete clinical remission after myeloablative allogeneic stem cell transplantation (al...
AbstractThe monitoring of minimal residual disease (MRD) through low sensitivity real-time (RT) poly...
Seventy-two patients with non-Hodgkin's lymphoma were evaluated for the presence of molecular marker...
Relapse has become the major cause of treatment failure after allogeneic hematopoietic stem cell tra...
Imatinib induces a high complete cytogenetic response (CCR) rate in relapsed chronic myelogenous leu...
Allogeneic stem cell transplantation (SCT) is the choice of therapy for leukemia patients who respon...
Current induction therapies for acute and chronic leukemias and the lymphomas have achieved signific...
BackgroundThe graft-versus-leukemia effect is able to induce clinical responses in patients with chr...
Background: The graft-versus-leukemia effect is able to induce clinical responses in patients with c...
The online version of this article contains a supplementary appendix. Background The graft-versus-le...
Reduced intensity allogeneic stem cell transplantation (RIC alloSCT) can lead to 50% of progression...
Background and Objectives: The molecular analysis of minimal residual disease (MRD) may provide info...
Quantification of minimal residual disease (MRD) following allogeneic hematopoietic cell transplanta...
In chronic lymphocytic leukemia (CLL), clonal rearrangement of the immunoglobulin heavy chain locus ...
Monitoring minimal residual disease is an important way to identify patients with acute myeloid leuk...
Patients in complete clinical remission after myeloablative allogeneic stem cell transplantation (al...
AbstractThe monitoring of minimal residual disease (MRD) through low sensitivity real-time (RT) poly...
Seventy-two patients with non-Hodgkin's lymphoma were evaluated for the presence of molecular marker...
Relapse has become the major cause of treatment failure after allogeneic hematopoietic stem cell tra...
Imatinib induces a high complete cytogenetic response (CCR) rate in relapsed chronic myelogenous leu...
Allogeneic stem cell transplantation (SCT) is the choice of therapy for leukemia patients who respon...
Current induction therapies for acute and chronic leukemias and the lymphomas have achieved signific...